POINT Biopharma Global Inc., (PNT) News

POINT Biopharma Global Inc., (PNT): $8.29

0.51 (+6.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PNT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter PNT News Items

PNT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PNT News Highlights

  • PNT's 30 day story count now stands at 4.
  • Over the past 16 days, the trend for PNT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • DRUG and VIEW are the most mentioned tickers in articles about PNT.

Latest PNT News From Around the Web

Below are the latest news stories about POINT Biopharma Global Inc that investors may wish to consider to help them evaluate PNT as an investment opportunity.

POINT Biopharma to Participate in Upcoming Virtual Investor Conferences

INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will participate in the following upcoming investor conferences. B. Riley Securities’ Radiation Oncology Investor DayFormat: Fireside chatDate: Tuesday, February 22, 2022Time: 11:30 am ET Cowen & Co.

Yahoo | February 17, 2022

POINT Biopharma Provides Early-Stage Program Updates

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Initiated IND-enabling studies for next-generation actinium-225 radiolabeled PSMA targeted program, PNT2001, to support an IND/CTA filing expected H1 2023 INDIANAPOLIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global

Yahoo | February 14, 2022

POINT Biopharma updates on manufacturing and late-stage studies

Recording the biggest intraday gain since Dember, POINT Biopharma (PNT +12.4%) has neared a two-month high after the company shared its latest updates on production and late-stage clinical trials. The company said that its Indianapolis manufacturing facility was launched in October 2021, and an Investigational New Drug (IND) amendment to...

Seeking Alpha | February 1, 2022

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in an abstract for the 2022 SNMMI Mid-Winter & ACNM Annual Meeting Randomization phase of the SPLASH trial initiat

Yahoo | February 1, 2022

Baskin Financial Services Inc. Buys CoStar Group Inc, Watsco Inc, Tricon Residential Inc, Sells ...

Toronto, A6, based Investment company Baskin Financial Services Inc. (Current Portfolio) buys CoStar Group Inc, Watsco Inc, Tricon Residential Inc, POINT Biopharma Global Inc, Broadcom Inc, sells Activision Blizzard Inc, Algonquin Power & Utilities Corp, Vanguard Short-Term Corporate Bond ETF, NVIDIA Corp, Bitfarms during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Baskin Financial Services Inc..

Yahoo | January 24, 2022

POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and autoimmune diseaseINDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the appointment of Matthew Vincent, Ph.D.

Yahoo | January 4, 2022

POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Company to pursue other opportunities Jonathan Ross Goodman elected Lead Independent Director of the Board of Directors INDIANAPOLIS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global acce

Yahoo | December 1, 2021

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

POINT adds key technology to accelerate in-house no-carrier-added Lu-177 productionINDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and Studiecentrum voor Kernenergie/Centre d’Etude de l’Energie Nucléaire, also known as the Belgian Nuclear Research Center (“SCK CEN”), one of Belgium’s largest research centers with sixty-five years

Yahoo | November 24, 2021

POINT Biopharma to Host Virtual Education Event on December 6, 2021

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 INDIANAPOLIS, Nov. 22, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced that it will host a virtual education event titled “The First Princ

Yahoo | November 22, 2021

POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update

Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an IND/CTA for PNT2004's lead, PNT6555, in the first half of 2022 Completed construction and commissioning of Indianapolis manufacturing facility with first clinical product shipment expected by the end of fiscal 2021 INDIANAPOLIS, Nov. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:

Yahoo | November 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4353 seconds.